scholarly article | Q13442814 |
P50 | author | Shitij Kapur | Q20713543 |
Eugenii A. Rabiner | Q56097267 | ||
Paola Piccini | Q64856193 | ||
Marios Politis | Q64856266 | ||
Flavia Niccolini | Q90879542 | ||
Graham E Searle | Q122914788 | ||
Roger N. Gunn | Q41909429 | ||
Sridhar Natesan | Q47504364 | ||
Nils Muhlert | Q47504365 | ||
Tiago Reis Marques | Q47504367 | ||
P2093 | author name string | Thomas Foltynie | |
Andri C Tziortzi | |||
P2860 | cites work | Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum | Q23909635 |
Statistical parametric maps in functional imaging: A general linear approach | Q27864122 | ||
Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A | Q28574633 | ||
Immunohistochemical localization of PDE10A in the rat brain | Q28581263 | ||
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain | Q29614725 | ||
Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia. | Q30493549 | ||
A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume | Q30970553 | ||
Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. | Q48463634 | ||
Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. | Q48546793 | ||
Fluid and white matter suppression with the MP2RAGE sequence. | Q48777579 | ||
Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. | Q48810366 | ||
Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. | Q48947947 | ||
Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. | Q49080012 | ||
Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum | Q49155446 | ||
Nonlinear spatial normalization using basis functions | Q53178416 | ||
Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade | Q33703262 | ||
Region of interest template for the human basal ganglia: comparing EPI and standardized space approaches | Q36476491 | ||
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease | Q36901896 | ||
History of falls in Parkinson disease is associated with reduced cholinergic activity | Q37459699 | ||
Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD | Q37536347 | ||
Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway | Q37543216 | ||
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients | Q37602233 | ||
Brain activity during complex imagined gait tasks in Parkinson disease | Q37695009 | ||
Integrating neurotransmission in striatal medium spiny neurons. | Q37986667 | ||
Deep brain stimulation for gait and postural symptoms in Parkinson's disease | Q38153335 | ||
In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654. | Q39180707 | ||
Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. | Q39205398 | ||
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. | Q39801798 | ||
A high resolution and high contrast MRI for differentiation of subcortical structures for DBS targeting: the Fast Gray Matter Acquisition T1 Inversion Recovery (FGATIR). | Q39988148 | ||
Cell communication, calcium ion, and cyclic adenosine monophosphate | Q41511554 | ||
PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology. | Q42487128 | ||
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease | Q42543320 | ||
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression | Q43820139 | ||
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
PET imaging shows loss of striatal PDE10A in patients with Huntington disease | Q45296605 | ||
Modification of Parkinsonism--chronic treatment with L-dopa | Q45300970 | ||
The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease | Q45302323 | ||
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. | Q46418668 | ||
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation | Q46904268 | ||
Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain | Q46976056 | ||
The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease | Q48119124 | ||
Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson's disease | Q48128786 | ||
Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy | Q48140763 | ||
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism? | Q48433626 | ||
P433 | issue | Pt 10 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 3003-3015 | |
P577 | publication date | 2015-07-25 | |
P1433 | published in | Brain | Q897386 |
P1476 | title | Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease | |
P478 | volume | 138 |
Q64968192 | A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys |
Q90198060 | Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development |
Q52099206 | Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease. |
Q48906405 | Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates. |
Q37560665 | Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain |
Q92217551 | Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme |
Q28390557 | Comparison of [(11)C]TZ1964B and [(18)F]MNI659 for PET imaging brain PDE10A in nonhuman primates |
Q47242194 | Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases |
Q48093702 | Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry |
Q45305673 | Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. |
Q36802579 | De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions |
Q64785657 | Imaging Markers of Progression in Parkinson's Disease |
Q31119042 | Imaging in Parkinson's disease. |
Q91621387 | Imaging phosphodiesterase-10a availability in cocaine use disorder with [11 C]IMA107 and PET |
Q50200295 | In vivo characterization of two 18F-labeled PDE10A PET radioligands in nonhuman primate brains. |
Q51640625 | Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005. |
Q31158920 | Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. |
Q85888036 | Neurodegenerative disease: Changes in brain phosphodiesterase 10A levels in neurodegenerative basal ganglia disorders |
Q52317290 | New Imaging Markers for Movement Disorders. |
Q26746978 | Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012 |
Q57456370 | PET Imaging in Movement Disorders |
Q42369736 | PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease |
Q46354756 | Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy |
Q38686069 | Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease |
Q39029199 | Phosphodiesterase 10 inhibitors in clinical development for CNS disorders |
Q26753116 | Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications |
Q42504663 | Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia. |
Q89972944 | Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease |
Q33635522 | Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study |
Q48272772 | TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia |
Q37740539 | The Phosphodiesterase 10A Inhibitor PF-2545920 Enhances Hippocampal Excitability and Seizure Activity Involving the Upregulation of GluA1 and NR2A in Post-synaptic Densities. |
Q92461195 | Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond |
Search more.